Onboarding Patients on JAK Inhibitors for Atopic Dermatitis - Episode 5
Safety Data of Oral JAK Inhibitors in Atopic Dermatitis
Published on:
An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.
Video content above is prompted by the following questions:
- Are there differences in safety data from clinical trials vs. real-world studies? What has been your clinical experience with abrocitinib and upadacitinib?
- Discuss your monitoring schedule for patients taking JAK inhibitors.
- How do you modify your monitoring protocol according to patient characteristics and preferences?
- How do you modify your monitoring protocol according to patient characteristics and preferences?
